The Potential of MiRNAs as Biomarkers and Therapy Targets for Cancer

Wargasetia, Teresa Liliana

doi:10.28932/jmh.v1i3.523

Cited by 3 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RNAse found in body fluids can degrade molecules, especially mRNA. MiRNA-21 can remain stable on heating, very low or high pH levels, long storage times, and repeated freeze-thawing ( 8 ). Apart from being stable, miRNA-21 testing is easy to detect and shows accurate results by using standard techniques such as RT-PCR, microarray and small RNA sequencing ( 9 ).…”

Section: Discussionmentioning

confidence: 99%

miRNA-21 Serum Evaluation in BPH, Hormone Sensitive Prostate Cancer, and Castrate Resistant Prostate Cancer: Attempt for Diagnostic Biomarker Evaluation

Seputra¹,

Purnomo²,

Susianti³

et al. 2021

Acta Inform Med

View full text Add to dashboard Cite

Background: Some of prostate cancer cases could progress to be Castrate Resistant Prostate Cancer (CRPC). However it is still a challenge to early diagnose it since no reliable examination could be done except PSA, which has high variability. It is now known that miRNAs are involved in nearly all inflammatory responses. Several malignancies in humans that specifically express miRNA have been detected and identified. The expression values of miRNA-21 also correlates with the occurrence of resistant castration of prostate cancer and metastases, therefore miRNA-21 is expected to be a biomarker to estimate the progression of cancer. Objective: The purpose of this study was to analyze the expression values and cut-off markers of miRNA-21 as markers of CRPC progression. Methods: This study used a retrospective cohort design with observational analysis. The forty-eight total sample was obtained from serum, then the RT-PCR was performed to obtain expression values of miRNA-21. Data were analyzed using One Way ANOVA to see the difference in the expression values of miRNA-21. Furthermore, to determine the cut-off analysis was carried out using the ROC curve. Results: In the BPH group, an average expression value of miRNA-21 was 33,785±1.80 ng/dL, in the Prostate cancer group the average miRNA-21 was 34.51±1.32 ng/dL, while in the CRPC group, an average miRNA-21 was obtained, reaching to 34.51±1.32 ng/dL. The cut-off value of miRNA-21 from the BPH category was <33,595, PPV = 50%, NPV = 80% with a value of p = 0.081, the prostate Ca category was 33.595–35.21, PPV = 87.5%, NPV = 66.7% with p value = 0.003, while the value of miRNA-21 in the CRPC category was> 35.21, PPV = 80%, NPV = 58.3 with a value of p = 0.04. Conclusion: There is a significant difference in the expression values of miRNA-21 between BPH with CRPC and Prostate cancer and CRPC, therefore, miRNA-21 cut-off point is potential to differentiate the diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

miRNA-21 Serum Evaluation in BPH, Hormone Sensitive Prostate Cancer, and Castrate Resistant Prostate Cancer: Attempt for Diagnostic Biomarker Evaluation

Seputra¹,

Purnomo²,

Susianti³

et al. 2021

Acta Inform Med

View full text Add to dashboard Cite

show abstract

“…Overexpression of MiRNA-21 in cancer causes cell motility and invasion to increase. MiRNA-21 acts as an oncogene by targeting specific genes such as PDCD4, PTEN, Bcl-2, STAT3 and so on [10][11][12] . Another miRNA family in NPC was miRNA-29c which serves as a tumor suppressor gene.…”

Section: Introductionmentioning

confidence: 99%

Expression of Micro RNA-21 and 29c in Blood Plasma of Patients with Nasopharyngeal Carcinoma

Savitri¹,

Safri²,

Djamin³

et al. 2017

J. of Medical Sciences

View full text Add to dashboard Cite

MicroRNA (miRNA) are small non-coding RNA molecules that work in post-transcription and can cause degradation and cell damage through the targeted gene. Damage to these cells influences the process of carcinogenesis. One of them is in nasopharyngeal carcinoma (NPC). Among families of miRNA that play a role in the pathogenesis of NPC that miRNA-21, miRNA-29c and which is closely associated with the progression, invasion and tumor metastasis. The purpose of this study was to determine the expression of miRNA-21 and miRNA-29c. Knowledge of these miRNA could help in the development of targeted therapy in carcinoma, as a biomarker diagnostic and clinical predictive and would be useful in therapeutic decision making. The research design was observational analytic study carried out in Wahidin Sudirohusodo Makassar, January-June, 2017. The collected blood plasma was isolated and then synthesized to cDNA and calculated quantitatively with qRT-PCR and analyzed using CFX manager 96. There were 52 samples consisting of 27 plasma NPC and 25 controls. From the plasma detected miRNA-21 and miRNA-29c. Expression of miRNA-21 increased 4.47795 fold compared with controls (p<0.05)) but its expression can not describe the progression of the tumor at a later stadium (p<0.05). In contrast, the expression of miRNA-29c decreased -119.317 fold compared with control, its regulation at a later stadium did not change significantly. Both miRNA-21 and miRNA-29c in blood plasma can use for NPC detection but a single microRNA examination is less able to provide an overview of progressivity.

show abstract

MicroRNA Expression Profile Selection for Cancer Staging Classification Using Backpropagation

Anjarwati

Wibowo

Adhy

et al. 2018

J. Phys.: Conf. Ser.

View full text Add to dashboard Cite

The Potential of MiRNAs as Biomarkers and Therapy Targets for Cancer

Cited by 3 publications

References 16 publications

miRNA-21 Serum Evaluation in BPH, Hormone Sensitive Prostate Cancer, and Castrate Resistant Prostate Cancer: Attempt for Diagnostic Biomarker Evaluation

miRNA-21 Serum Evaluation in BPH, Hormone Sensitive Prostate Cancer, and Castrate Resistant Prostate Cancer: Attempt for Diagnostic Biomarker Evaluation

Expression of Micro RNA-21 and 29c in Blood Plasma of Patients with Nasopharyngeal Carcinoma

MicroRNA Expression Profile Selection for Cancer Staging Classification Using Backpropagation

Contact Info

Product

Resources

About